Adavosertib Before Surgery in Treating Patients With Advanced High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Public ClinicalTrials.gov record NCT02659241. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Pilot Study of Wee1 Inhibition Induction Prior to Tumor Reductive Surgery in Ovarian Cancer
Study identification
- NCT ID
- NCT02659241
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Early Phase 1
- Enrollment
- 38 participants
Conditions and interventions
Conditions
- Advanced Fallopian Tube Carcinoma
- Advanced Ovarian Carcinoma
- Advanced Primary Peritoneal Carcinoma
- Carcinomatosis
- Fallopian Tube High Grade Serous Adenocarcinoma
- Ovarian High Grade Serous Adenocarcinoma
- Primary Peritoneal High Grade Serous Adenocarcinoma
- Stage III Fallopian Tube Cancer AJCC v7
- Stage III Ovarian Cancer AJCC v6 and v7
- Stage III Primary Peritoneal Cancer AJCC v7
- Stage IIIA Fallopian Tube Cancer AJCC v7
- Stage IIIA Ovarian Cancer AJCC v6 and v7
- Stage IIIA Primary Peritoneal Cancer AJCC v7
- Stage IIIB Fallopian Tube Cancer AJCC v7
- Stage IIIB Ovarian Cancer AJCC v6 and v7
- Stage IIIB Primary Peritoneal Cancer AJCC v7
- Stage IIIC Fallopian Tube Cancer AJCC v7
- Stage IIIC Ovarian Cancer AJCC v6 and v7
- Stage IIIC Primary Peritoneal Cancer AJCC v7
- Stage IV Fallopian Tube Cancer AJCC v6 and v7
- Stage IV Ovarian Cancer AJCC v6 and v7
- Stage IV Primary Peritoneal Cancer AJCC v7
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 3, 2016
- Primary completion
- Dec 30, 2026
- Completion
- Dec 30, 2026
- Last update posted
- Apr 14, 2026
2016 – 2026
United States locations
- U.S. sites
- 8
- U.S. states
- 2
- U.S. cities
- 5
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| OHSU Knight Cancer Institute | Portland | Oregon | 97239 | — |
| MD Anderson in The Woodlands | Conroe | Texas | 77384 | — |
| Memorial Hermann Memorial City Medical Center | Houston | Texas | 77024 | — |
| M D Anderson Cancer Center | Houston | Texas | 77030 | — |
| The Woman's Hospital of Texas | Houston | Texas | 77054 | — |
| MD Anderson West Houston | Houston | Texas | 77079 | — |
| MD Anderson League City | League City | Texas | 77573 | — |
| MD Anderson in Sugar Land | Sugar Land | Texas | 77478 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Advanced Fallopian Tube Carcinoma trials
Other public records listing Advanced Fallopian Tube Carcinoma. Sorted by last update posted; newest first. Not a recommendation.
- NCT05969860: At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer Recruiting
- NCT05092373: Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax Recruiting
- NCT06639074: Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial Recruiting
- NCT02650986: Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1 Active, not recruiting
- NCT04616534: Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors Active, not recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02659241, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 14, 2026 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02659241 live on ClinicalTrials.gov.